

## **Fractional Flow Reserve Market - Global Outlook & Forecast 2024-2029**

Market Report | 2024-08-06 | 314 pages | Arizton Advisory & Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4200.00
- Team License \$4999.00
- Enterprisewide \$5999.00

### **Report description:**

The global fractional flow reserve market is expected to grow at a CAGR of 15.36% from 2023 to 2029.

### **MARKET TRENDS & DRIVERS**

#### **Next-Generation Devices Augmenting Non-Invasive FFR Methods**

FFR is considered the gold standard in determining the hemodynamic significance of coronary artery disease lesions. Despite encouragement and more benefits, the use of FFR is limited because it requires the use of vasodilator drugs, such as adenosine, which can increase procedure time, costs, and patient discomfort. However, the next generation of products has changed the scenario for patients and end-users. For instance, Acist Medical Systems, a Bracco Group Company, launched its ACIST RXi Mini System, the next-generation RXi Rapid Exchange FFR System, in the fractional flow reserve (FFR) market. The RXi Mini is designed to provide FFR measurements to complement angiography, provide qualitative assessment of lesion severity, and inform intervention strategy in diagnosing and treating coronary and peripheral artery disease.

#### **Favorable Reimbursement Support & Regulatory Approvals**

In the dynamic landscape of healthcare technology, reimbursement support, and regulatory approvals are pivotal factors that shape market opportunities, particularly in advanced diagnostic tools like FFR. Regulatory approvals are essential for ensuring the safety, efficacy, and quality of medical devices like FFR systems. Regulatory bodies, such as the FDA in the US, CE Mark in Europe, and national health authorities in other regions, assess and approve FFR devices based on rigorous clinical and technical evaluations. Furthermore, the convergence of favorable reimbursement support and regulatory approvals creates significant opportunities in the fractional flow reserve market. Access to reimbursement drives market growth by incentivizing healthcare providers to integrate FFR technology into routine clinical practice, expanding the addressable market for FFR devices. Regulatory approvals spur innovation in FFR technology, leading to developing next-generation devices with enhanced features, such as wireless FFR systems, AI-driven algorithms for real-time data analysis, and integration with digital health platforms.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Increasing Number of CATH Labs

Cath Labs are specialized facilities with advanced imaging technology and interventional equipment primarily used for diagnosing and treating various cardiovascular conditions. These labs enable cardiologists to perform diagnostic procedures such as coronary angiography, FFR measurements, and therapeutic interventions like angioplasty and stenting. The availability and accessibility of Cath Labs are crucial factors in delivering timely and effective cardiovascular care. Out-of-hospital facilities have become important care settings for routine, minimally invasive procedures. Image-guided procedures have become one of the significant parts of hospitals. One such procedure is the FFR, and an FFR CT procedure is largely performed in CATH Labs. In cardiac CATH labs, FFR usage has gone high and supported the growth of the fractional flow reserve market. One of the major advantages of the use of FFR is that it distinguishes significant lesions from non-significant lesions in patients with accurate coronary syndrome and patients with multivessel CAD undergoing urgent or elective catheterization.

## SEGMENTATION INSIGHTS

### INSIGHTS BY TECHNOLOGY

By technology, the global fractional flow reserve market is segmented into non-invasive and invasive monitoring (FFR guidewires and FFR systems). The non-invasive monitoring segment holds the majority of the segmental share in 2023. Non-invasive FFR technology, particularly FFR derived from coronary computed tomography angiography (FFR-CT), represents a significant advancement. This method uses advanced imaging and computational algorithms to assess the hemodynamic significance of coronary stenoses without requiring invasive procedures. Non-invasive technology eliminates the risks associated with invasive procedures, improving patient comfort and safety. It can be used for initial diagnosis and ongoing monitoring, expanding its use beyond interventional settings. Non-invasive FFR is gaining traction due to its convenience and safety, with significant uptake in regions with advanced healthcare systems. Advances in imaging technology and computational algorithms continue to enhance the accuracy and reliability of non-invasive FFR. Furthermore, the invasive FFR provides precise and reliable measurements for accurately assessing coronary lesions. The technology offers real-time feedback during procedures, aiding immediate clinical decision-making. Invasive FFR is well-supported by clinical guidelines from major cardiology societies, promoting its use in clinical practice.

#### Segmentation by Technology

- Non-invasive Monitoring
- Invasive Monitoring
- FFR Guidewires
- FFR Systems

### INSIGHTS BY APPLICATION

The single-vessel application holds the most significant share of the global fractional flow reserve market 2023. In single-vessel disease, FFR is used to assess the severity of stenosis in one coronary artery. This application is crucial for determining whether a single lesion significantly impairs blood flow and warrants intervention. FFR provides highly accurate diagnostic information, helping to distinguish hemodynamically significant lesions from those that are not. This reduces unnecessary procedures and focuses treatment on clinically relevant stenoses. For single-vessel disease, FFR helps interventional cardiologists make informed decisions about the need for percutaneous coronary intervention (PCI) or stenting. Also, in multi-vessel disease, FFR is used to evaluate multiple coronary arteries to identify which stenoses are functionally significant. This comprehensive approach is essential for planning complex revascularization strategies.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Segmentation by Applications

- Single-Vessel
- Multi-Vessel

## INSIGHTS BY END-USER

The global fractional flow reserve market by end-user is segmented into hospitals, office-based labs, diagnostic imaging centers, and others. The hospitals segment held the most dominant global market share in 2023. Hospitals lead the market due to their advanced infrastructure and high patient volumes, while office-based labs offer efficiency and cost advantages. Diagnostic imaging centers expand their diagnostic capabilities with FFR integration, and other end-users like academic institutions, ASCs, and emerging markets drive innovation and broader adoption. Also, hospitals have state-of-the-art catheterization labs necessary for performing FFR procedures. Their advanced infrastructure supports the adoption of complex technologies. Hospitals handle many cardiac patients, increasing the demand for accurate diagnostic tools like FFR to guide clinical decisions and improve patient outcomes. Hospitals provide a wide range of diagnostic and therapeutic services, allowing for integrated patient care and the use of FFR in conjunction with other treatments. Furthermore, diagnostic imaging centers focus on providing accurate and timely diagnostic services, making FFR a valuable addition to their capabilities. These centers can integrate FFR technology with other imaging modalities (e.g., CT, MRI), enhancing the comprehensiveness of cardiovascular assessments. Diagnostic imaging centers offer patients easier access to advanced diagnostic tools in various settings.

## Segmentation by End-User

- Hospitals
- Office-based Labs
- Diagnostic Imaging Centers
- Others

## GEOGRAPHICAL ANALYSIS

North America dominated the global fractional flow reserve market, accounting for a share of 39% in 2023. Driven by the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong adoption of innovative technologies, the regional market is poised for continued expansion. Key players such as Abbott, Boston Scientific, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and HeartFlow lead the market with their cutting-edge products and solutions. Despite challenges related to costs, training, and competitive technologies, the future of the FFR market in North America looks promising, with trends pointing towards greater integration with digital health, AI, non-invasive technologies, and efforts to improve healthcare access.

The Europe fractional flow reserve market is poised for significant growth, driven by the rising prevalence of CAD, technological advancements, supportive clinical evidence, and economic benefits. However, the market must address challenges related to cost, technical complexity, regulatory compliance, and competition from non-invasive techniques. Future trends, including the integration with digital health, miniaturization, hybrid diagnostic approaches, and a focus on patient-centered care, will shape the evolution of the market. As the FFR market continues to expand, it will play a crucial role in enhancing the diagnosis and management of coronary artery disease, ultimately improving patient outcomes and healthcare efficiency across Europe. Furthermore, the APAC fractional flow reserve market is poised for substantial growth, driven by rising cardiovascular disease prevalence, technological advancements, increased healthcare expenditure, and supportive government policies. Also, governments in the APAC region are investing heavily in healthcare infrastructure and advanced medical technologies. Increased healthcare spending facilitates adopting FFR technology in hospitals and clinics.

## Segmentation by Geography?

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- North America
  - o US
  - o Canada
- Europe
  - o Germany
  - o France
  - o UK
  - o Italy
  - o Spain
  - o Russia
  - o Netherlands
- APAC
  - o Japan
  - o China
  - o India
  - o South Korea
  - o Australia
- Latin America
  - o Brazil
  - o Mexico
  - o Argentina
  - o Colombia
- Middle East & Africa
  - o Turkey
  - o Saudi Arabia
  - o South Africa
  - o UAE

## VENDOR LANDSCAPE

The global fractional flow reserve market is highly consolidated, with limited players accounting for a significant market share. Major players dominate the market; however, new entrants have significant growth opportunities. Though the market is dominated by major players, many investigational and small med-tech companies are coming into existence with innovative products and technologies. This indicates that the fractional flow reserve market offers incredible growth opportunities for existing and future/emerging players due to a large pool of patient population with coronary heart diseases and other conditions and comorbidities, resulting in the need for cardiac diagnosis of the patient. Also, most major players focus on implementing strategies such as product launch and approval, marketing and promotion activities, acquisitions, increased R&D investment, and strengthening distribution networks to increase market share and presence.

## Key Company Profiles

- Abbott?
- ACIST Medical Systems
- Boston Scientific
- CathWorks
- GE Healthcare
- HeartFlow

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Keya Medical
- Koninklijke Philips
- Opsens Medical (Haemonetics)
- Siemens Healthineers

#### KEY QUESTIONS ANSWERED:

- 1.□How big is the global fractional flow reserve market?
- 2.□Who are the key players in the global fractional flow reserve market?
- 3.□What is the growth rate of the global fractional flow reserve market?
- 4.□What are the significant trends in the fractional flow reserve market?
- 5.□Which region dominates the global fractional flow reserve market share?

#### Table of Contents:

- 1.□SCOPE & COVERAGE
  - 1.1.□MARKET DEFINITION
    - 1.1.1.□INCLUSIONS
    - 1.1.2.□EXCLUSIONS
    - 1.1.3.□MARKET ESTIMATION CAVEATS
  - 1.2.□MARKET SEGMENTATION
    - 1.2.1.□MARKET BY TECHNOLOGY
    - 1.2.2.□MARKET BY APPLICATIONS
    - 1.2.3.□MARKET BY END-USER
    - 1.2.4.□REGIONS & COUNTRIES COVERED
  - 1.3.□MARKET DERIVATION
    - 1.3.1.□BASE YEAR
- 2.□PREMIUM INSIGHTS
  - 2.1.□OPPORTUNITY POCKETS
  - 2.2.□OVERVIEW
- 3.□MARKET AT A GLANCE
- 4.□INTRODUCTION
  - 4.1.□OVERVIEW
  - 4.2.□FFR: AN OVERVIEW
- 5.□MARKET OPPORTUNITIES & TRENDS
  - 5.1.□NEXT-GENERATION DEVICES AUGMENTING NON-INVASIVE FFR METHODS
  - 5.2.□FFR-OCT IMPROVING OUTCOMES IN DIABETIC PATIENTS
  - 5.3.□AI & ML REVOLUTIONIZING FFR-CT
  - 5.4.□FAVORABLE REIMBURSEMENT SUPPORT & REGULATORY APPROVALS
- 6.□MARKET GROWTH ENABLERS
  - 6.1.□NEW TECHNOLOGY DIRECTIONS IN FFR
  - 6.2.□RISING PREVALENCE OF CORONARY ARTERY DISEASE
  - 6.3.□INCREASING NUMBER OF CATH LABS
- 7.□MARKET RESTRAINTS
  - 7.1.□HIGH COST OF FFR
  - 7.2.□LIMITATIONS ASSOCIATED WITH FFR
  - 7.3.□LOW FFR ADOPTION & AVAILABILITY OF SUBSTITUTES
- 8.□MARKET LANDSCAPE

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.1. □ MARKET OVERVIEW
- 8.2. □ MARKET SIZE & FORECAST
- 8.3. □ FIVE FORCES ANALYSIS
  - 8.3.1. □ THREAT OF NEW ENTRANTS
  - 8.3.2. □ BARGAINING POWER OF SUPPLIERS
  - 8.3.3. □ BARGAINING POWER OF BUYERS
  - 8.3.4. □ THREAT OF SUBSTITUTES
  - 8.3.5. □ COMPETITIVE RIVALRY
- 9. □ TECHNOLOGY
  - 9.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 9.2. □ MARKET OVERVIEW
  - 9.3. □ NON-INVASIVE MONITORING
    - 9.3.1. □ MARKET OVERVIEW
    - 9.3.2. □ MARKET SIZE & FORECAST
    - 9.3.3. □ NON-INVASIVE MONITORING MARKET BY GEOGRAPHY
  - 9.4. □ INVASIVE MONITORING
    - 9.4.1. □ MARKET OVERVIEW
    - 9.4.2. □ MARKET SIZE & FORECAST
    - 9.4.3. □ FFR GUIDEWIRES
    - 9.4.4. □ MARKET SIZE & FORECAST
    - 9.4.5. □ FFR SYSTEMS
    - 9.4.6. □ MARKET SIZE & FORECAST
    - 9.4.7. □ INVASIVE MONITORING BY GEOGRAPHY
- 10. □ APPLICATIONS
  - 10.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 10.2. □ MARKET OVERVIEW
  - 10.3. □ SINGLE-VESSEL
    - 10.3.1. □ MARKET OVERVIEW
    - 10.3.2. □ MARKET SIZE & FORECAST
    - 10.3.3. □ SINGLE-VESSEL BY GEOGRAPHY
  - 10.4. □ MULTI-VESSEL
    - 10.4.1. □ MARKET OVERVIEW
    - 10.4.2. □ MARKET SIZE & FORECAST
    - 10.4.3. □ MULTI-VESSEL BY GEOGRAPHY
- 11. □ END-USER
  - 11.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 11.2. □ MARKET OVERVIEW
  - 11.3. □ HOSPITALS
    - 11.3.1. □ MARKET OVERVIEW
    - 11.3.2. □ MARKET SIZE & FORECAST
    - 11.3.3. □ HOSPITALS BY GEOGRAPHY
  - 11.4. □ OFFICE-BASED LABS
    - 11.4.1. □ MARKET OVERVIEW
    - 11.4.2. □ MARKET SIZE & FORECAST
    - 11.4.3. □ OFFICE-BASED LABS BY GEOGRAPHY
  - 11.5. □ DIAGNOSTIC IMAGING CENTERS
    - 11.5.1. □ MARKET OVERVIEW

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.5.2. □ MARKET SIZE & FORECAST
- 11.5.3. □ DIAGNOSTIC IMAGING CENTERS BY GEOGRAPHY
- 11.6. □ OTHERS
- 11.6.1. □ MARKET OVERVIEW
- 11.6.2. □ MARKET SIZE & FORECAST
- 11.6.3. □ OTHERS BY GEOGRAPHY
- 12. □ GEOGRAPHY
- 12.1. □ MARKET SNAPSHOT & GROWTH ENGINE
- 12.2. □ GEOGRAPHIC OVERVIEW
- 13. □ NORTH AMERICA
- 13.1. □ MARKET OVERVIEW
- 13.2. □ MARKET SIZE & FORECAST
- 13.2.1. □ NORTH AMERICA BY TECHNOLOGY
- 13.2.2. □ NORTH AMERICA BY APPLICATION
- 13.2.3. □ NORTH AMERICA BY END-USER
- 13.3. □ KEY COUNTRIES
- 13.3.1. □ US: MARKET SIZE & FORECAST
- 13.3.2. □ CANADA: MARKET SIZE & FORECAST
- 14. □ EUROPE
- 14.1. □ MARKET OVERVIEW
- 14.2. □ MARKET SIZE & FORECAST
- 14.2.1. □ EUROPE BY TECHNOLOGY
- 14.2.2. □ EUROPE BY APPLICATION
- 14.2.3. □ EUROPE BY END-USER
- 14.3. □ KEY COUNTRIES
- 14.3.1. □ GERMANY: MARKET SIZE & FORECAST
- 14.3.2. □ FRANCE: MARKET SIZE & FORECAST
- 14.3.3. □ UK: MARKET SIZE & FORECAST
- 14.3.4. □ ITALY: MARKET SIZE & FORECAST
- 14.3.5. □ SPAIN: MARKET SIZE & FORECAST
- 14.3.6. □ RUSSIA: MARKET SIZE & FORECAST
- 14.3.7. □ NETHERLANDS: MARKET SIZE & FORECAST
- 15. □ APAC
- 15.1. □ MARKET OVERVIEW
- 15.2. □ MARKET SIZE & FORECAST
- 15.2.1. □ APAC BY TECHNOLOGY
- 15.2.2. □ APAC BY APPLICATION
- 15.2.3. □ APAC BY END-USER
- 15.3. □ KEY COUNTRIES
- 15.3.1. □ JAPAN: MARKET SIZE & FORECAST
- 15.3.2. □ CHINA: MARKET SIZE & FORECAST
- 15.3.3. □ INDIA: MARKET SIZE & FORECAST
- 15.3.4. □ SOUTH KOREA: MARKET SIZE & FORECAST
- 15.3.5. □ AUSTRALIA: MARKET SIZE & FORECAST
- 16. □ LATIN AMERICA
- 16.1. □ MARKET OVERVIEW
- 16.2. □ MARKET SIZE & FORECAST

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.2.1. □LATIN AMERICA BY TECHNOLOGY
- 16.2.2. □LATIN AMERICA BY APPLICATION
- 16.2.3. □LATIN AMERICA BY END-USER
- 16.3. □KEY COUNTRIES
- 16.3.1. □BRAZIL: MARKET SIZE & FORECAST
- 16.3.2. □MEXICO: MARKET SIZE & FORECAST
- 16.3.3. □ARGENTINA: MARKET SIZE & FORECAST
- 16.3.4. □COLOMBIA: MARKET SIZE & FORECAST
- 17. □MIDDLE EAST & AFRICA
- 17.1. □MARKET OVERVIEW
- 17.2. □MARKET SIZE & FORECAST
- 17.2.1. □MIDDLE EAST & AFRICA BY TECHNOLOGY
- 17.2.2. □MIDDLE EAST & AFRICA BY APPLICATION
- 17.2.3. □MIDDLE EAST & AFRICA BY END-USER
- 17.3. □KEY COUNTRIES
- 17.3.1. □TURKEY: MARKET SIZE & FORECAST
- 17.3.2. □SAUDI ARABIA: MARKET SIZE & FORECAST
- 17.3.3. □SOUTH AFRICA: MARKET SIZE & FORECAST
- 17.3.4. □UAE: MARKET SIZE & FORECAST
- 18. □COMPETITIVE LANDSCAPE
- 18.1. □COMPETITION OVERVIEW
- 18.2. □MARKET SHARE ANALYSIS
- 18.2.1. □ABBOTT
- 18.2.2. □ACIST MEDICAL SYSTEMS
- 18.2.3. □BOSTON SCIENTIFIC
- 18.2.4. □CATHWORKS
- 18.2.5. □GE HEALTHCARE
- 18.2.6. □HEARTFLOW
- 18.2.7. □KEYA MEDICAL
- 18.2.8. □KONINKLIJKE PHILIPS
- 18.2.9. □OPSENS
- 18.2.10. □SIEMENS HEALTHINEERS
- 19. □KEY COMPANY PROFILES
- 19.1. □ABBOTT
- 19.1.1. □BUSINESS OVERVIEW
- 19.1.2. □PRODUCT OFFERINGS
- 19.1.3. □KEY STRATEGIES
- 19.1.4. □KEY STRENGTHS
- 19.1.5. □KEY OPPORTUNITIES
- 19.2. □ACIST MEDICAL SYSTEMS
- 19.2.1. □BUSINESS OVERVIEW
- 19.2.2. □PRODUCT OFFERINGS
- 19.2.3. □KEY STRATEGIES
- 19.2.4. □KEY STRENGTHS
- 19.2.5. □KEY OPPORTUNITIES
- 19.3. □BOSTON SCIENTIFIC
- 19.3.1. □BUSINESS OVERVIEW

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



- 19.3.2. □PRODUCT OFFERINGS
- 19.3.3. □KEY STRATEGIES
- 19.3.4. □KEY STRENGTHS
- 19.3.5. □KEY OPPORTUNITIES
- 19.4. □CATHWORKS
- 19.4.1. □BUSINESS OVERVIEW
- 19.4.2. □PRODUCT OFFERINGS
- 19.4.3. □KEY STRATEGIES
- 19.4.4. □KEY STRENGTHS
- 19.4.5. □KEY OPPORTUNITIES
- 19.5. □GE HEALTHCARE
- 19.5.1. □BUSINESS OVERVIEW
- 19.5.2. □PRODUCT OFFERINGS
- 19.5.3. □KEY STRATEGIES
- 19.5.4. □KEY STRENGTHS
- 19.5.5. □KEY OPPORTUNITIES
- 19.6. □HEARTFLOW INC.
- 19.6.1. □BUSINESS OVERVIEW
- 19.6.2. □PRODUCT OFFERINGS
- 19.6.3. □KEY STRATEGIES
- 19.6.4. □KEY STRENGTHS
- 19.6.5. □KEY OPPORTUNITIES
- 19.7. □KEYA MEDICAL
- 19.7.1. □BUSINESS OVERVIEW
- 19.7.2. □PRODUCT OFFERINGS
- 19.7.3. □KEY STRATEGIES
- 19.7.4. □KEY STRENGTHS
- 19.7.5. □KEY OPPORTUNITIES
- 19.8. □KONINKLIJKE PHILIPS
- 19.8.1. □BUSINESS OVERVIEW
- 19.8.2. □PRODUCT OFFERINGS
- 19.8.3. □KEY STRATEGIES
- 19.8.4. □KEY STRENGTHS
- 19.8.5. □KEY OPPORTUNITIES
- 19.9. □OPSENS MEDICAL (HAEMONETICS)
- 19.9.1. □BUSINESS OVERVIEW
- 19.9.2. □PRODUCT OFFERINGS
- 19.9.3. □KEY STRATEGIES
- 19.9.4. □KEY STRENGTHS
- 19.9.5. □KEY OPPORTUNITIES
- 19.10. □SIEMENS HEALTHINEERS
- 19.10.1. □BUSINESS OVERVIEW
- 19.10.2. □PRODUCT OFFERINGS
- 19.10.3. □KEY STRATEGIES
- 19.10.4. □KEY STRENGTHS
- 19.10.5. □KEY OPPORTUNITIES
- 20. □REPORT SUMMARY

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

20.1.	KEY TAKEAWAYS
20.2.	STRATEGIC RECOMMENDATIONS
21.	QUANTITATIVE SUMMARY
21.1.	MARKET BY TECHNOLOGY
21.1.1.	NORTH AMERICA BY TECHNOLOGY
21.1.2.	EUROPE BY TECHNOLOGY
21.1.3.	APAC BY TECHNOLOGY
21.1.4.	LATIN AMERICA BY TECHNOLOGY
21.1.5.	MIDDLE EAST & AFRICA BY TECHNOLOGY
21.2.	MARKET BY APPLICATION
21.2.1.	NORTH AMERICA BY APPLICATION
21.2.2.	EUROPE BY APPLICATION
21.2.3.	APAC BY APPLICATION
21.2.4.	LATIN AMERICA BY APPLICATION
21.2.5.	MIDDLE EAST & AFRICA BY APPLICATION
21.3.	MARKET BY END-USER
21.3.1.	NORTH AMERICA BY END-USER
21.3.2.	EUROPE BY END-USER
21.3.3.	APAC BY END-USER
21.3.4.	LATIN AMERICA BY END-USER
21.3.5.	MIDDLE EAST & AFRICA BY END-USER
21.4.	MARKET BY GEOGRAPHY
21.4.1.	NON-INVASIVE MONITORING MARKET BY GEOGRAPHY
21.4.2.	INVASIVE MONITORING BY GEOGRAPHY
21.4.3.	SINGLE-VESSEL BY GEOGRAPHY
21.4.4.	MULTI-VESSEL BY GEOGRAPHY
21.4.5.	HOSPITALS BY GEOGRAPHY
21.4.6.	OFFICE-BASED LABS BY GEOGRAPHY
21.4.7.	DIAGNOSTIC IMAGING CENTERS BY GEOGRAPHY
21.4.8.	OTHERS BY GEOGRAPHY
22.	APPENDIX
22.1.	RESEARCH METHODOLOGY
22.2.	RESEARCH PROCESS
22.3.	REPORT ASSUMPTIONS & CAVEATS
22.3.1.	KEY CAVEATS
22.3.2.	CURRENCY CONVERSION
22.4.	ABBREVIATIONS

## Fractional Flow Reserve Market - Global Outlook & Forecast 2024-2029

Market Report | 2024-08-06 | 314 pages | Arizton Advisory & Intelligence

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4200.00
	Team License	\$4999.00
	Enterprisewide	\$5999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-24"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com